Centessa Pharmaceuticals PLC ADR (CNTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has a cash flow conversion efficiency ratio of -0.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-72.22 Million) by net assets ($487.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Centessa Pharmaceuticals PLC ADR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Centessa Pharmaceuticals PLC ADR - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Centessa Pharmaceuticals PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TCL Zhonghuan Renewable Energy Technology Co Ltd
SHE:002129
|
0.024x |
|
MERUS N.V. EO -09
F:2GH
|
N/A |
|
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság
F:MGYB
|
0.097x |
|
Isupetasys
KO:007660
|
0.066x |
|
Kymera Therapeutics Inc
NASDAQ:KYMR
|
-0.058x |
|
Nice Ltd ADR
NASDAQ:NICE
|
0.049x |
|
Anhui Yingliu
SHG:603308
|
0.017x |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
Annual Cash Flow Conversion Efficiency for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CNTA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.86 Million | $-193.82 Million | -0.368x | -3.99% |
| 2024-12-31 | $401.55 Million | $-142.06 Million | -0.354x | +47.88% |
| 2023-12-31 | $236.24 Million | $-160.34 Million | -0.679x | -13.77% |
| 2022-12-31 | $336.17 Million | $-200.55 Million | -0.597x | -115.40% |
| 2021-12-31 | $491.55 Million | $-136.14 Million | -0.277x | +91.93% |
| 2020-12-31 | $3.10 Million | $-10.63 Million | -3.431x | -704.88% |
| 2019-12-31 | $13.66 Million | $-5.83 Million | -0.426x | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more